 DELRAY BEACH, Fla., Nov. 10, 2020 GLOBE NEWSWIRE -- AzurRx BioPharma, Inc. NASDAQ:AZRX AzurRx or the Company, a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced that it has signed a binding letter of intent with Asymchem, a leading global contract development and manufacturing service CDMO provider, for the development and production of MS1819 for the treatment of exocrine pancreatic insufficiency. 